Autopsy report · NCT00216424

Capecitabine (Xeloda) and Radiation for Patients With Rectosigmoid Carcinoma

“lack of accrual”

The sponsor’s own words in the registry.

Life of this trial

• Registered 7 months after it had already started.
• Ran for about 1 year 11 months before it stopped.
• 40 participants planned (an estimate, not an actual count).
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 4

Sponsor

James A. Haley Veterans Administration Hospital

Sponsor type

US federal agency

Conditions

Colorectal Cancer

Interventions

Capecitabine (Xeloda)

Participants

40 (planned, not actual)

Sites

1

Countries

United States

Trials that died the same way

• Phase II Study to Evaluate Fenofibrate Therapy in Patients With Smoldering or Symptomatic Multiple Myeloma
  “Lack of adequate accrual.” (92% match in meaning)
• Effect of Metformin on Biomarkers of Colorectal Tumor Cell Growth
  “Inadequate accrual” (90% match in meaning)
• Dexamethasone in Reducing Everolimus-Induced Oral Stomatitis in Patients With Cancer
  “Severe lack of accrual” (90% match in meaning)
• Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy
  “Poor accrual” (86% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.